Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNX-102 SL in Fibromyalgia (RESILIENT)
NCT05273749Phase 3Completed
- Sponsor
- Tonix Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Nov 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in fibromyalgia (FM) comparing TNX-102 SL with Placebo (2 arms). Primary endpoint: Change From Baseline to the Week 14 Endpoint in the Diary NRS Weekly Average of Daily Self Reported Average Pain Severity Scores. Started Apr 2022; status: completed.
02
Drugs
Tonmya
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT05273749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05273749.